ALVO
Alvotech
NASDAQ: ALVO · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$3.30
-6.25% today
Updated 2026-04-29
Market cap
$1.03B
P/E ratio
33.00
P/S ratio
1.75x
EPS (TTM)
$0.10
Dividend yield
—
52W range
$3 – $12
Volume
0.6M
Alvotech (ALVO) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $31.92M | $66.62M | $36.77M | $83.03M | $91.43M | $489.68M | $586.32M |
| Revenue growth (YoY) | — | +108.7% | -44.8% | +125.8% | +10.1% | +435.6% | +19.7% |
| Cost of revenue | — | $0.00 | $0.00 | $64.09M | $160.86M | $185.31M | $235.56M |
| Gross profit | $31.92M | $66.62M | $36.77M | $18.93M | $-69.42M | $304.37M | $350.76M |
| Gross margin | 100.0% | 100.0% | 100.0% | 22.8% | -75.9% | 62.2% | 59.8% |
| R&D | $95.56M | $148.07M | $191.01M | $180.62M | $210.83M | $171.31M | $184.19M |
| SG&A | $48.57M | $58.91M | $84.13M | $186.74M | $73.04M | $61.45M | $90.95M |
| Operating income | $-61.45M | $-137.54M | $-235.46M | $-346.44M | $-354.86M | $69.64M | $78.21M |
| Operating margin | -192.5% | -206.5% | -640.3% | -417.3% | -388.1% | 14.2% | 13.3% |
| EBITDA | $-99.02M | $-177.88M | $-18.03M | $-439.80M | $-493.67M | $-32.27M | $323.39M |
| EBITDA margin | -310.2% | -267.0% | -49.0% | -529.7% | -539.9% | -6.6% | 55.2% |
| EBIT | $-113.63M | $-194.30M | $-36.23M | $-460.21M | $-517.88M | $-63.58M | $285.54M |
| Interest expense | $95.75M | $97.47M | $112.97M | $91.44M | $134.82M | $157.60M | $149.19M |
| Income tax | $491000.00 | $-121.73M | $-47.69M | $-38.07M | $-99.32M | $14.30M | — |
| Effective tax rate | -0.2% | 41.7% | 32.0% | 6.9% | 15.3% | -6.6% | 0.0% |
| Net income | $-209.88M | $-170.04M | $-101.50M | $-513.58M | $-551.73M | $-231.86M | $27.92M |
| Net income growth (YoY) | — | +19.0% | +40.3% | -406.0% | -7.4% | +58.0% | +112.0% |
| Profit margin | -657.5% | -255.3% | -276.0% | -618.6% | -603.4% | -47.3% | 4.8% |